Document is current

Article History

Accepted: 9 July 2024

First Online: 8 August 2024

Competing interests

: C.C. reports grants from the Italian Ministry of Health and Fondazione Ricerca Fibrosi Cistica and fees for clinical trials by Vertex Pharmaceuticals, with payments made to the institution; personal fees for consulting from Vertex Pharmaceuticals, Chiesi and Viatrix; and is unpaid Deputy Editor of the <i>Journal of Cystic Fibrosis</i> and Scientific Director of the Fondazione Ricerca Fibrosi Cistica. J.C.D. reports research grants from UK Cystic Fibrosis Trust, Cystic Fibrosis Foundation, Cystic Fibrosis Ireland, Engineering and Physical Sciences Research Council, and National Institute for Health and Care Research, with payments made to the institution; personal fees for clinical trial leadership and/or advisory board and speaking roles for Vertex Pharmaceuticals, Boehringer Ingelheim, Eloxx, Algipharma, Abbvie, Arcturus, Enterprise Therapeutics, Recode, LifeArc, Genentech and Tavanta; and is unpaid Deputy Editor for the <i>Journal of Cystic Fibrosis</i> and President Elect of the European Cystic Fibrosis Society. M.A.M. reports grants from the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the German Innovation Fund, and an independent medical grant from Vertex Pharmaceuticals, with payments made to the institution; personal fees for advisory board participation or consulting from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Splisense and Vertex Pharmaceuticals; lecture honoraria from Vertex Pharmaceuticals; travel support from Boehringer Ingelheim and Vertex Pharmaceuticals; and is unpaid Associate Editor of the <i>European Respiratory Journal</i> and Fellow of the European Respiratory Society (FERS). P.-R.B. reports grants from Vaincre la Mucoviscidose, Filière Maladies Rares MUCO-CFTR, the French Cystic Fibrosis Society, GSK and Vertex Pharmaceuticals, with payments made to the institution; personal fees for advisory boards/lectures from AstraZeneca, Chiesi, GSK, Insmed, Vertex Pharmaceuticals, Viatris and Zambon; travel support for attending symposia from AstraZeneca and Chiesi; and is an unpaid Member of the Scientific Council of the European Cystic Fibrosis Society, Member of the Scientific Council of the French Cystic Fibrosis patient association (Vaincre la Mucoviscidose), Director of the French Cystic Fibrosis Reference Network and President of the French Cystic Fibrosis Society 2023–2027. J.L.T.-C. reports grants from the Cystic Fibrosis Foundation and National Institutes of Health; fees for clinical trials by 4DMT, Vertex Pharmaceuticals, Boehringer Ingelheim and Eloxx, with payments made to the institution; personal fees for consulting and/or advisory boards from Insmed, 4DMT, Vertex Pharmaceuticals and AbbVie; personal financial support from non-commercial sources for services as adult patient care representative to the Cystic Fibrosis Foundation Board of Trustees, Cystic Fibrosis Foundation’s Clinical Research Executive Committee, Clinical Research Advisory Board, Racial Justice Working Group, the Cystic Fibrosis Therapeutics Development Network Sexual Health, Reproduction and Gender Research-Working Group, scientific advisory board for Emily’s Entourage, American Thoracic Society (ATS) Respiratory Research Awards Committee; Member of the ATS Scientific Grant Review committee; Chair-Elect for the ATS International Conference Committee; and is an unpaid Member of the International Advisory Board for <i>Lancet Respiratory Medicine</i> and the Editorial Board for the <i>Journal of Cystic Fibrosis</i>. M.S. reports grants from the National Institutes of Health, Cystic Fibrosis Foundation, Flight Attendant Medical Research Institute, State of Florida, and COPD Foundation, with payments made to the institution as well as personal fees for consulting from Arrowhead Pharmaceuticals.